2-乙酰基-4-戊酮酸乙酯 | 41892-81-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 2-乙酰基-4-戊酮酸乙酯
• 英文名称: ethyl 2-acetyl-4-oxopentanoate
• 英文别名: 2-acetyl-4-oxopentanoic acid ethyl ester；ethyl 2-acetyl-4-oxovalerate
• CAS: 41892-81-3
• 化学式: C₉H₁₄O₄
• mdl: MFCD00204229
• 分子量: 186.208
• InChiKey: WANUOLLLVOSMFL-UHFFFAOYSA-N

物化性质

• 沸点：
  126-128 °C(Press: 14 Torr)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918300090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Ethyl 2-Acetyl-4-Oxopentanoate
: TMT00517
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 186,21 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
Ethyl 2-Acetyl-4-Oxopentanoate
Eye Irrit. 2; H319 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
Ethyl 2-Acetyl-4-Oxopentanoate
Xi, R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-乙酰基-4-戊酮酸乙酯 在 potassium carbonate 作用下， 生成 2,5-己二酮
  参考文献：
  名称：

  Dann et al., Chemische Berichte, 1952, vol. 85, p. 457,460

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙酰基-4-戊酸乙酯 在 碘 、 4-甲基苯磺酸吡啶 、 sodium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 水 、 乙腈 、 苯 为溶剂， 反应 72.0h， 生成 2-乙酰基-4-戊酮酸乙酯
  参考文献：
  名称：

  Antonioletti, Roberto; Bonadies, Francesco; Scettri, Arrigo, Gazzetta Chimica Italiana, 1991, vol. 121, # 5, p. 233 - 234

  摘要：

  DOI：

文献信息

• Pyridazinones for the treatment of cancer
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2955182A1

  公开（公告）日：2015-12-16

  The present invention relates to novel substituted pyrrolo- and pyrazolopyridazinones, as well as pharmaceutical compositions containing at least one of these substituted pyrrolo- and pyrazolo- pyridazinones together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said novel substituted pyrrolo- and pyrazolo- pyridazinones are binding to the prenyl binding pocket of PDEδ and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDEδ to K-Ras and of Ras signaling in cells.

  本发明涉及新型取代吡咯并吡唑吡啶酮，以及含有至少一种这些新型取代吡咯并吡唑吡啶酮的药物组合物，该药物组合物还包括至少一种药用可接受的载体、赋形剂和/或稀释剂。所述新型取代吡咯并吡唑吡啶酮结合到PDEδ的藤黄素结合口袋，因此，通过抑制PDEδ与K-Ras的结合以及细胞中Ras信号传导的结合，对癌症的预防和治疗具有用处。
• Preparation and Reactivities of (η³-1- and 2-Trimethylsiloxyallyl)Fe(CO)₂NO Complexes. Intermediates Functioning as Equivalents of β- and α-Acyl Carbocations and Acyl Carbanions
  作者：Keiji Itoh、Saburo Nakanishi、Yoshio Otsuji

  DOI：10.1246/bcsj.64.2965

  日期：1991.10

  (η3-1- and 2-Trimethylsiloxyallyl)Fe(CO)2NO complexes were prepared by the reaction of the corresponding siloxyallylic halides with Bu4N[Fe(CO)3NO]. These complexes reacted with both of carbon nucleophiles and carbon electrophiles preferentially at the less hindered sites of the allylic ligands. In these reactions, (η3-1-trimethylsiloxyallyl)Fe(CO)2NO complexes served as synthetically equivalent synthons

  (η3-1-和2-三甲基甲硅烷氧基烯丙基)Fe(CO)2NO配合物是通过相应的甲硅烷氧基烯丙基卤化物与Bu4N[Fe(CO)3NO]反应制备的。这些配合物优先与碳亲核试剂和碳亲电试剂在烯丙基配体的受阻较小的位点反应。在这些反应中，(η3-1-三甲基甲硅烷氧基烯丙基)Fe(CO)2NO 配合物作为 β-酰基碳正离子和 j8-酰基碳负离子和 (η3-2-三甲基甲硅烷氧基烯丙基)Fe(CO)2NO 配合物的合成等效合成子α-酰基碳正离子和α-酰基碳负离子。描述了反应的立体化学过程。
• Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site
  作者：Sandip Murarka、Pablo Martín-Gago、Carsten Schultz-Fademrecht、Alaa Al Saabi、Matthias Baumann、Eyad K. Fansa、Shehab Ismail、Peter Nussbaumer、Alfred Wittinghofer、Herbert Waldmann

  DOI：10.1002/chem.201603222

  日期：2017.5.2

  The K‐Ras GTPase is a major target in anticancer drug discovery. However, direct interference with signaling by K‐Ras has not led to clinically useful drugs yet. Correct localization and signaling by farnesylated K‐Ras is regulated by the prenyl binding protein PDEδ. Interfering with binding of PDEδ to K‐Ras by means of small molecules provides a novel opportunity to suppress oncogenic signaling. Here

  K‐Ras GTPase是抗癌药物发现的主要目标。但是，对K‐Ras信号转导的直接干扰尚未导致临床上有用的药物。异戊二烯结合蛋白PDEδ调节法尼基化的K-Ras的正确定位和信号传导。通过小分子干扰PDEδ与K-Ras的结合提供了抑制致癌信号的新机会。在这里，我们介绍了基于吡咯并吡啶并酮和吡唑并并吡并并酮以低纳摩尔亲和力与PDEδ的法呢基结合袋结合的新型K-Ras-PDEδ抑制剂化学型的鉴定和结构导向的发展。我们描述了基于吡唑并吡啶并嗪酮的K-Ras-PDEδ抑制剂的结构-性质关系以及体内药代动力学（PK）和毒物动力学（Tox）研究。
• Understanding the Scope of Feist-Bénary Furan Synthesis: Chemoselectivity and Diastereoselectivity of the Reaction Between α-Halo Ketones and β-Dicarbonyl Compounds
  作者：Yi Peng、Juan Luo、Qiang Feng、Qiang Tang

  DOI：10.1002/ejoc.201600975

  日期：2016.10

  application of a Paal–Knorr synthesis. In this manuscript, we investigate the chemoselectivity and diastereoselectivity of furan synthesis from α-halo ketones and β-dicarbonyl compounds, by carrying out the separation and characterization of the intermediates involved in the reaction. Additionally, a one-pot Feist–Benary furan synthesis from α-halo ketones and β-dicarbonyl compounds without any base or solvent

  Feist-Benary 呋喃合成，即 α-卤代羰基和 β-二羰基化合物之间的反应，被认为是生成许多不同类型的 C-3 羰基呋喃的有效方法。然而，也有报道称，在类似的反应条件下，中间体三羰基物质可以通过应用 Paal-Knorr 合成进一步转化为替代的呋喃异构体。在本手稿中，我们通过对反应中涉及的中间体进行分离和表征，研究了由 α-卤代酮和 β-二羰基化合物合成呋喃的化学选择性和非对映选择性。此外，还开发了一种由 α-卤代酮和 β-二羰基化合物在没有任何碱或溶剂的情况下合成 Feist-Benary 呋喃的一锅法。
• [EN] BENZYLAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZYLAMINE
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2014108679A1

  公开（公告）日：2014-07-17

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

  本发明提供了化合物的公式(I)：包含这种化合物的组合物；在治疗中使用这种化合物（例如在涉及血浆激肽酶活性的疾病或病况的治疗或预防中）；以及使用这种化合物治疗患者的方法；其中R1至R3，R5至R9，A，P，V，W，X，Y和Z如本文所定义。